Keysight partners with NVIDIA on quantum-AI computing architecture
Neuraxis, Inc. (NYSE American:NRXS) reported preliminary unaudited financial results for the third quarter ended September 30, 2025. According to a press release statement based on a recent SEC filing, the company expects to have approximately $4.4 million in cash and cash equivalents as of September 30, 2025. InvestingPro analysis indicates the company is quickly burning through cash, though it maintains more cash than debt on its balance sheet.
For the three months ended September 30, 2025, Neuraxis estimates net sales of about $0.8 million and gross profits of roughly $0.7 million. The company anticipates an operating loss of approximately $2.1 million for the quarter. The company maintains a strong gross profit margin of 84.5%, according to InvestingPro data, though analysts do not expect profitability this year.
For the nine-month period ended September 30, 2025, preliminary net sales are expected to be about $2.6 million, compared to approximately $1.9 million for the same period in 2024. This growth aligns with the company’s impressive revenue growth rate of 41.9% over the last twelve months.
The company stated that these figures are preliminary and unaudited. Neuraxis noted that its independent registered public accounting firm has not audited or reviewed these estimates, and final results may differ as the company completes its quarter-end financial statement close process.
Neuraxis is classified as an emerging growth company and its common stock is listed on the NYSE American exchange under the symbol NRXS. The information is based on a press release statement contained in a recent SEC filing.
In other recent news, Neuraxis Inc. reported a significant 46% increase in revenue for the second quarter of 2025 compared to the same period last year. This revenue growth highlights the company’s efforts in product expansion and market penetration. Despite experiencing an operating loss, Neuraxis remains optimistic about its future growth, supported by new FDA indications and strategic initiatives. Additionally, Neuraxis entered into an At The Market Offering Agreement with Craig-Hallum Capital Group LLC, allowing the company to offer and sell up to $3.3 million of its common stock. This agreement, executed on August 29, 2025, provides Neuraxis with the flexibility to sell shares at its discretion. The sales will be conducted under an effective registration statement on Form S-3, previously filed with the SEC. These recent developments reflect Neuraxis’s strategic approach to enhancing its market position and financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.